2seventy bio’s Post

A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Still wondering about #theranostics and the impact of this technology for patients? Theranostics, a groundbreaking fusion of "therapy" and "diagnostics," represents a revolutionary approach to personalized medicine. The combination of using one radiopharmaceutical to identify (diagnose) and a second radiopharmaceutical to deliver therapy to treat disease has provided a unique opportunity to craft highly-specific and targeted therapies with high efficacy and great clinical impact for patients. 👉 Learn more about theranostics: #nuclearmedicine  #radiopharmaceuticals #iqmedicalservices

Calling all #lupus specialists & researchers: The April edition of our Literature Highlights & detailed slide decks are now available on the Lupus-Forum, featuring key advancements in lupus research and therapeutics. This month, we delve into topics such as the safety and efficacy of CD19 #CAR-T cell therapy, the role of #anifrolumab in treating #SLE, the establishment of autoantigen-specific Treg-cell-based therapy in #LN, and the latest on cardiovascular risk factors in #SLE patients: https://lnkd.in/dCk9aBNk

𝐖𝐡𝐚𝐭 𝐡𝐚𝐩𝐩𝐞𝐧𝐞𝐝 𝐢𝐧 𝐂𝐑𝐈𝐒𝐏𝐑 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐭𝐡𝐢𝐬 𝐰𝐞𝐞𝐤?? Here's 3 picks, and you can check out our latest newsletter for the full overview! 1️⃣ HuidaGene Therapeutics presented very promising pre-clinical data for a potentially new therapy for Duchenne muscular dystropy 📈 2️⃣ The FDA has cleared KSQ Therapeutics, Inc. application to begin a clinical trial of KSQ-004EX in solid tumours 💉 3️⃣ Researchers in the US propose a new therapeutic strategy for amyotrophic lateral sclerosis and frontotemporal dementia 🧠 #crisprmedicinenews #crisprmedicine #crispr #crisprtrial #cmnweekly #geneediting #raredisease #cancertherapy https://lnkd.in/eBHkVREe

Important article discussing Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS). In conclusion, SPMs after CAR T represented a small fraction of the AE reports in FAERS. The disproportionality analysis suggests an increased risk of reporting certain SPMs, notably myeloid and T-cell malignancies. The low numbers do not provide conclusive evidence of the risk of SPMs after CAR T therapy. Dedicated registries to study SPMs post CAR T can offer valuable insights for patient care and future development. This becomes pertinent as CAR T therapies expand to nonmalignant conditions 24. Finally, the primary cause of mortality in relapses or refractory hematologic malignancies remains the primary disease. https://lnkd.in/eY74W78P

Potential new mesothelioma drug extends survival. Integration of Pegargiminase with initial chemotherapy treatments could enhance the therapeutic results in patients suffering from nonepithelioid pleural mesothelioma, targeting to improve patient outcomes.#MesotheliomaAdvancements https://buff.ly/42Z3ZSN

Potential new mesothelioma drug extends survival. Integration of Pegargiminase with initial chemotherapy treatments could enhance the therapeutic results in patients suffering from nonepithelioid pleural mesothelioma, targeting to improve patient outcomes.#MesotheliomaAdvancements https://buff.ly/42Z3ZSN

targeting both of CD19 and CD22 is one of the options for Antigen 19 loss besides other tumor related resistance mechanisms

Hot off the press our paper on use of PBPK in assessment of DDI, organ impairment, and biopharmaceutics in healthy subjects and cancer patients! Noriko Okudaura Howard Burt

At #ESMO24, late-breaking primary results from the DESTINYBreast-12 trial revealed substantial and durable efficacy with the antibody–drug conjugate (#ADC) trastuzumab deruxtecan in patients with HER2+ metastatic #BreastCancer, including those with brain metastases. Encouraging data were also presented from the smaller ICARUS-BREAST01 study with the novel anti-HER3 ADC patritumab deruxtecan in patients with HR+/HER2- #AdvancedBreastCancer after failure of CDK-4/6 inhibitor therapy. 👉Read the full-data commentary by Philippe Aftimos MD on the #ESMODailyReporter https://ow.ly/gRCQ50TmTCX